

In collaboration with
Samarkand State Medical University
Clinical & Molecular Biomedicine (CMB) is an international, peer-reviewed, open-access journal dedicated to research that connects molecular discoveries with clinical applications.
The journal promotes interdisciplinary work bridging laboratory science and clinical medicine so that advances in molecular biology can be translated into improved diagnosis, treatment, and patient care.
CMB publishes studies across translational medicine, molecular and cellular biology, clinical biochemistry, genomics and epigenetics, proteomics and metabolomics, microbiome research, molecular oncology, neurobiology, biomarker discovery, drug discovery and resistance, gene and cell therapy, precision medicine, and immunology and vaccinology.
The journal is committed to rigorous peer review, ethical publishing, transparent reporting, and reproducible biomedical research.
Clinical & Molecular Biomedicine (CMB) is an international, peer-reviewed, open-access journal that publishes high-quality research connecting molecular discoveries with clinical applications.
The journal provides a platform for scientists, clinicians, and biomedical researchers to disseminate advances in translational medicine that improve understanding, diagnosis, and treatment of human diseases.
The journal aims to promote interdisciplinary research bridging basic molecular science and clinical medicine, enabling the translation of laboratory discoveries into improved patient care.
The journal focuses on translational biomedical research integrating molecular biology, clinical medicine, and emerging biomedical technologies in the following research areas:
Translational medicine
Molecular and cellular biology
Clinical biochemistry
Genomics and epigenetics
Proteomics and metabolomics
Microbiome research
Molecular oncology
Neurobiology
Biomarker discovery
Drug discovery and resistance
Gene and cell therapy
Precision medicine
Immunology and vaccinology
The mission of CMB is to promote research that moves discoveries from bench to bedside, accelerating the development of diagnostics, therapeutics, and personalized medicine.
The journal is committed to rigorous, fair, and timely peer review by experts in the field.
Clinical & Molecular Biomedicine adheres to the highest standards of research ethics, data reporting, and reproducibility, ensuring that all published work is both scientifically sound and clinically meaningful.
Rigorous peer-review process
Open access publishing
No article processing charge (APC)
Rapid editorial decision
Global editorial board
International authorship
Clinical & Molecular Biomedicine (CMB) publishes innovative research that advances understanding of disease mechanisms and clinical interventions.
The primary aim of CMB is to publish studies that explain the molecular mechanisms underlying human diseases and translate these findings into clinically meaningful outcomes.
The journal welcomes interdisciplinary studies combining experimental, computational, and clinical research approaches.
Genomics and Epigenetics
Proteomics and Metabolomics
Translational Oncology
Molecular Neurobiology
Biomarker Discovery
Drug Target Discovery
Precision Medicine
Identification of disease-associated genetic variants and epigenetic modifications.
Discovery of molecular biomarkers and metabolic pathways associated with disease.
Research focusing on cancer biomarkers, molecular diagnostics, and targeted therapies.
Studies investigating molecular mechanisms of neurological disorders.
Identification and validation of diagnostic, prognostic, and therapeutic biomarkers.
Research identifying novel molecular targets for therapeutic intervention.
Integration of molecular data for personalized therapeutic strategies.
The journal accepts several categories of manuscripts.
Original Research Articles: Full-length reports describing novel experimental or clinical findings.
Review Articles: Comprehensive and critical reviews summarizing current knowledge in a specific field.
Short Communications: Brief reports presenting important preliminary findings.
Case Reports: Clinical observations offering novel insights into disease or treatment.
Methods and Protocols: Descriptions of new techniques or improved experimental methodologies.
Letters to the Editor: Comments or discussions related to previously published articles.
This journal follows a single anonymized review process.
Your submission will initially be assessed by our editors to determine suitability for publication in this journal.
If your submission is deemed suitable, it will typically be sent to a minimum of two reviewers for an independent expert assessment of the scientific quality.
The decision as to whether your article is accepted or rejected will be taken by our editors.
The Editor-in-Chief has final authority over all editorial decisions.
Possible decisions include:
Accept
Minor revision
Major revision
Reject
CMB follows internationally recognized publication ethics guidelines from organizations such as:
Committee on Publication Ethics (COPE)
International Committee of Medical Journal Editors (ICMJE)
World Association of Medical Editors (WAME)
Original research only
No plagiarism or duplicate publication
Accurate reporting of data
Proper citation of sources
Ethical approval for human and animal research
When authors submit an article to a journal of EditoryPress, it is implied that:
The work described has not been published previously except in the form of a preprint, an abstract, a published lecture, an academic thesis, or a registered report.
The article is not under consideration for publication elsewhere.
The article's publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out.
If accepted, the article will not be published elsewhere in the same form, in English or in any other language, including electronically, without the written consent of the copyright-holder.
The following statements must be included in your submitted manuscript under the heading 'Statements and Declarations'. This should be placed after the References section.
All authors must disclose any financial or personal relationships with individuals or organizations that could inappropriately influence, or be perceived to influence, their work.
A conflict of interest (COI) exists when professional judgment concerning a primary interest may be influenced by a secondary interest.
Research funding or grants
Employment or consultancy
Honoraria or speaking fees
Patents or patent applications
Stock ownership or other financial investments
Advisory or leadership roles in organizations
Institutional or professional affiliations
Personal relationships
Academic competition
Strong intellectual, ideological, or political positions that may affect interpretation of results
Authors must clearly disclose all sources of financial support received for the conduct of the research and/or the preparation of the manuscript.
Authors should state the role of the funding organization or sponsor, if any, in the following aspects of the study:
Study design
Data collection
Data analysis and interpretation
Manuscript preparation
Decision to submit the manuscript for publication
The journal encourages the use of inclusive and respectful language in all submitted manuscripts.
Authors should ensure that their writing avoids expressions that could imply that one individual or group is superior to another based on characteristics such as:
Age
Gender
Race
Ethnicity
Culture
Sexual orientation
Disability or health condition
Research involving humans, animals, or eukaryotic cells should consider sex- and gender-based analyses (SGBA) when relevant.
Authors are encouraged to:
Consider sex and/or gender variables during study design and data analysis when appropriate.
Clearly describe how sex and/or gender were considered in the research methodology.
Address the influence of sex or gender in the interpretation of results, when relevant.
Acknowledge any limitations in the generalizability of the findings if sex- or gender-based analyses were not conducted.
Authors submitting manuscripts to CMB must ensure that their work is original, unpublished, and not under consideration, in part or in full, either in print or electronic format, by another journal.
Before finalizing the submission of your manuscript, authors are strongly advised to carefully review the following checklist to ensure completeness and compliance with journal requirements:
One author has been clearly designated as the corresponding author, and complete contact details, including email address, full postal address, and telephone number have been provided.
All required files have been uploaded successfully. This includes the main manuscript, keywords, figure captions, tables, supplementary materials, and any video or multimedia files, where applicable.
The manuscript has undergone thorough spelling and grammar checks to ensure clarity and accuracy of language.
All references cited within the text are included in the reference list, and all references listed are appropriately cited in the text.
Necessary permissions have been obtained for any copyrighted material reproduced from other sources, including online content.
Please follow the hyperlink “Submit manuscript” and upload all of your manuscript files following the instructions given on the screen.
Please ensure you provide all relevant editable source files at every submission and revision. For your manuscript text, please always submit in common word processing formats such as .docx or LaTeX.
Please note that Author Contribution information and Competing Interest information must be provided at submission via the submission interface.
A cover letter must accompany every submission and should:
Describe the scope, importance, and novelty of the manuscript.
Disclose any potential competing interests.
Confirm originality and exclusivity of submission to CMB.
Acknowledge author contributions and funding sources.
Suggest potential reviewers and optionally request exclusion of up to 5 reviewers.
Provide complete contact details for all authors, identifying the corresponding author clearly.
For submissions to Clinical & Molecular Biomedicine (CMB), authors are required to provide editable source files for all components of the manuscript, including the main text, figures, tables, and graphical elements.
Providing editable files facilitates efficient handling during the peer-review, copyediting, and production processes.
File Format: Manuscripts must be submitted in an editable format. Use .doc or .docx for Microsoft Word files and .tex for LaTeX submissions. PDF files are not accepted as source files for manuscript submissions.
Document Layout: Manuscripts prepared in Microsoft Word should use a single-column layout. Double-column formatting is permitted only for manuscripts prepared using LaTeX.
Clean Formatting: Before submission, authors should remove tracked changes, strikethrough text, and unnecessary underlining from the manuscript, unless such formatting is scientifically relevant to the content of the article.
Language and Formatting Check: Authors are encouraged to use spell-check and grammar-check tools to ensure clarity, accuracy, and consistency in language throughout the manuscript.
Formatting guidelines: Manuscripts should be submitted in Word.
Use a normal, plain font (e.g., 12-point Times Roman) for text with 1.5 line spacing.
Use italics for emphasis.
Use the automatic page numbering function to number the pages.
Do not use field functions.
Use tab stops or other commands for indents, not the space bar.
Use the table function, not spreadsheets, to make tables.
Use the equation editor or MathType for equations.
Save your file in docx format (Word 2007 or higher) or doc format (older Word versions).
Tables in editable Word format (separate or embedded in the text file)
Figures as high-resolution editable artwork (separate or embedded in the text file)
Manuscripts should be organized in the following sections:
Title page
Abstract
Keywords
Introduction
Materials and Methods
Results
Discussion
Conclusions
Funding
Acknowledgments
References
Figure legends
Tables and figures
The title page should include the following information:
Article Title
Author Names
Author Affiliations
Corresponding Author
Present or Permanent Address
Abstracts must be able to stand alone, as abstracts are often presented separately from the article. The abstract should be 150–250 words and include:
Background
Methods
Key results
Conclusions
Provide 4–6 keywords for indexing purposes.
Tables should be prepared in an editable text format and must not be submitted as images.
Tables must be numbered consecutively using Arabic numerals according to the order in which they are first mentioned in the text.
Each table should be cited in the manuscript text in sequential numerical order.
Tables should be placed as close as possible to the relevant text within the manuscript or on separate pages at the end of the document.
Every table must include a clear, descriptive, and concise caption positioned above the table.
Footnotes should be used where necessary and placed directly below the table body.
Authors should avoid vertical lines, excessive formatting, or cell shading.
High-quality figures are essential for effectively conveying the complexity and significance of translational research.
All figures should be submitted as separate high-resolution files, in addition to being appropriately placed within the manuscript.
Figure files should be named consecutively using the format Fig followed by the figure number (e.g., Fig1.tiff, Fig2.eps).
Vector graphics: Preferred formats are EPS or PDF, with all fonts embedded.
Halftone images/photographs: Preferred format is TIFF.
Other acceptable formats: JPG and PNG (meeting resolution requirements).
MS Office files (.docx, .pptx) are acceptable only if figures are properly embedded and maintain adequate resolution.
Photographs/halftone images: 300 dpi
Combination figures (images with text/line elements): 500–600 dpi
Line art (black and white, no shading): 1000–1200 dpi
Color figures are published free of charge in the online version.
Submit color images in RGB format (8 bits per channel).
Authors must ensure that figures remain clear and interpretable when converted to grayscale for print.
Use standard sans-serif fonts such as Arial or Helvetica.
Maintain consistent font type and size across all figures.
Recommended font size: 8–12 pt.
All text must remain legible after resizing for publication.
Lines must be clear and sharp, with a minimum thickness of 0.1 mm (0.3 pt).
Avoid decorative elements such as shadows, gradients, or outlined text.
For images involving magnification, scale bars must be included within the figure.
Figures must be numbered consecutively using Arabic numerals according to their order of appearance.
All figures must be cited in the manuscript text in sequential order.
Multi-panel figures should be labeled using lowercase letters (a, b, c).
Captions must be provided in the main manuscript file, not within the figure image.
Each caption should begin with “Fig.” followed by the figure number.
Captions should include a concise descriptive title, a clear explanation of figure content, and identification of all symbols and abbreviations.
Figures should be placed close to their first citation in the manuscript or grouped at the end.
Single-column width: approximately 84 mm.
Double-column width: approximately 174 mm.
All elements within the figure must remain clear and legible at the intended publication size.
The use of generative artificial intelligence (AI) or AI-assisted tools to create or modify figures is generally not permitted.
An exception may be made when AI tools are used as part of the research methodology. In such cases, authors must provide full transparency in the Methods section.
AI-generated artwork requires prior editorial approval, along with appropriate disclosure and attribution.
Authors are encouraged to submit supplementary material to support and enhance the scientific content of their manuscripts.
Supplementary material may include extended datasets, additional figures and tables, high-resolution images, multimedia files (audio/video), software, protocols, or other supporting information that is directly relevant to the study.
Supplementary files must be accurate, relevant, and directly related to the research presented in the manuscript.
All supplementary materials must be clearly cited and appropriately referenced within the manuscript text.
Authors must submit all supplementary files simultaneously with the initial manuscript submission.
Each supplementary file should include a clear, concise, and descriptive caption.
Supplementary materials may be added, updated, or replaced only during the revision stage.
Clinical & Molecular Biomedicine (CMB) welcomes the submission of video files and animation sequences that enhance the presentation of scientific content.
All video and multimedia content must be clearly referenced within the manuscript text.
Each file should be assigned a descriptive and logically structured filename.
Videos should be submitted in commonly accepted file formats and must not exceed 150 MB per file or a total of 1 GB for all submitted multimedia files.
Authors must provide a representative still image (snapshot) for each video file.
A concise and descriptive explanation of each video’s content should be included in the manuscript.
The journal supports open, transparent, and reproducible research practices and strongly encourages authors to share their research data wherever possible.
Deposit research data in a recognized public repository, where appropriate.
Cite and link datasets within the manuscript to facilitate access and verification.
Provide sufficient methodological and contextual information to enable other researchers to interpret, validate, and reuse the data.
Authors are encouraged to include a Data Availability Statement in their manuscript. This statement should clearly indicate:
Where and how the data can be accessed (e.g., repository name, accession number, or persistent link), or
The reasons for restricted access, where applicable.
Footnotes should be used sparingly and only when necessary to provide additional clarification that cannot be integrated into the main text without disrupting its flow.
Footnotes must be numbered consecutively throughout the manuscript.
Authors are encouraged to use the automatic footnote feature available in word-processing software.
Alternatively, footnotes may be indicated within the text and compiled in a separate section at the end of the manuscript.
Authors may acknowledge individuals, institutions, or organizations that provided support or assistance during the course of the research or the preparation of the manuscript.
Acknowledgements must be presented in a separate section titled “Acknowledgements”, placed immediately before the reference list.
Only individuals or entities who made meaningful but non-authorship contributions are acknowledged.
All acknowledged individuals have given permission to be named, where applicable.
All references cited in the manuscript must be included in the reference list, and all entries in the reference list must be cited in the text.
References cited in the abstract must also be provided in full in the reference list.
Unpublished results and personal communications should generally not be included in the reference list.
References cited as “in press” indicate that the work has been accepted for publication but is not yet available in final form.
Authors must ensure that all reference details are accurate and complete at the time of submission.
Clinical & Molecular Biomedicine (CMB) follows a numbered citation style:
References should be indicated by numbers in square brackets within the text.
References must be numbered consecutively in the order in which they first appear in the manuscript.
Where appropriate, author names may be mentioned in the text, but the corresponding reference number must always be included.
Authors who wish to include figures, tables, or text excerpts that have been previously published must obtain written permission from the original copyright holder(s) prior to submission.
The granted permission must explicitly allow use of the material in both print and online formats of Clinical & Molecular Biomedicine (CMB).
Obtain all necessary permissions before submitting the manuscript.
Ensure that permissions cover the intended scope of reuse.
Provide documented evidence of permission at the time of submission.
All research involving human participants, human data, animals, or animal-derived materials must adhere to the highest ethical standards.
Authors are required to include the following mandatory statements under the “Statements and Declarations” section of the manuscript.
Authors must confirm that the study was conducted in accordance with established ethical guidelines and was approved by the appropriate institutional or national authority.
A formal statement must indicate that the study received approval (or exemption) from a recognized body such as an Institutional Review Board (IRB), Ethics Committee, or Institutional Animal Care and Use Committee (IACUC).
The statement must include the full name of the approving body, along with the approval/reference number and date, where applicable.
For all studies involving human participants, authors must confirm that freely given, informed consent was obtained.
A statement confirming that consent was obtained from all participants must be included in the manuscript.
For minors or vulnerable populations, consent must be obtained from parents or legal guardians.
If the manuscript includes any identifiable individual data, authors must obtain explicit consent for publication from the individual concerned.
A statement confirming that consent to publish has been obtained must be included in the manuscript.
Authors are encouraged to ensure that their manuscript is written in clear, concise, and grammatically correct English.
English language editing
Developmental and structural feedback
Manuscript formatting
Figure preparation
Translation services
Upon acceptance of the manuscript, authors will be required to complete a publishing agreement.
The corresponding author will receive an email containing a secure link to the online agreement form.
Authors retain full copyright ownership of their work.
By choosing open access publication, authors agree to publish their article under a Creative Commons Attribution (CC BY) license, which permits:
Redistribution
Reuse and adaptation
Commercial use provided that appropriate credit is given to the original authors and source
The primary purpose of the proof stage is to identify and correct typesetting, formatting, or conversion errors, and to ensure the overall accuracy and completeness of the manuscript.
The corresponding author will receive access to an online proofing system.
This system functions similarly to a word processor, enabling authors to edit text, comment on figures and tables, and respond to queries raised by the copy editor.
Substantial changes to content are not permitted at this stage without prior approval from the Editor.
Accepted articles are published online shortly after the corrected proofs are received.
This Online First version represents the official first publication and is fully citable using its DOI.
All articles published in Clinical & Molecular Biomedicine (CMB) are made available through a fully open-access model, ensuring immediate and unrestricted access to readers worldwide.
Article Processing Charges (APCs) – FREE
Currently, no article processing charges are required for publication.
Increased accessibility
Greater visibility and impact
Compliance with funding requirements
Immediate and unrestricted access to all articles
Publication under the CC BY license
Promotion of equitable access to scientific knowledge regardless of institutional or financial constraints
To maintain the integrity and reliability of the scholarly record, the journal may issue formal notices in cases where errors or concerns arise after publication.
Authors are expected to uphold the highest standards of integrity, transparency, and accountability in the conduct and reporting of their research.
Any violation of these principles constitutes research misconduct and will be addressed in accordance with internationally recognized ethical guidelines, including those of the Committee on Publication Ethics (COPE).
The journal maintains a strict policy against all forms of academic and research misconduct.
Erratum – to correct errors introduced during publication
Corrigendum – to correct errors made by the authors
Expression of Concern – issued when there are unresolved concerns about the integrity of the work
Retraction – issued in cases of significant errors or ethical issues that invalidate the findings
Depending on the findings, the journal may take one or more of the following actions:
Rejection of the manuscript
Publication of a formal correction
Retraction of the published article
Notification of the authors’ affiliated institutions or funding bodies
International peer-reviewed open-access journal focused on translational biomedicine.
Publishes work connecting molecular science with clinically meaningful diagnosis and treatment.
Welcomes molecular, experimental, computational, and clinical biomedical research.
Uses single anonymized peer review with editorial screening and at least two reviewers for suitable submissions.
Publishes under CC BY and currently does not require an APC.
Clinical & Molecular Biomedicine (CMB) is an international, peer-reviewed, open-access journal that publishes research connecting molecular discoveries with clinical applications.
The journal provides a platform for scientists, clinicians, and biomedical researchers to share translational work that advances understanding of disease mechanisms and supports better diagnosis, treatment, and patient care.
Translational medicine
Molecular biology
Clinical biochemistry
Genomics and epigenetics
Biomarker discovery
Precision medicine

© 2026 Clinical & Molecular Biomedicine. All rights reserved.